Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma

Abstract

In an Australian clinical practice setting, ipilimumab achieved efficacy and tolerability measures similar to those reported in clinical trials. The frequency and severity of ipilimumab-related AEs (including death) are notable, and treatment should occur under the supervision of an experienced clinical team.